Contentious House USPTO Oversight Hearing Centers on PTAB Reforms, Trump’s Political Influence

Today, the U.S. House of Representatives Judiciary Committee’s Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet conducted its first oversight hearing of the U.S. Patent and Trademark Office (USPTO) during the second Trump Administration. The harshest lines of questioning for USPTO Director John Squires during the hearing were reserved for the agency’s notice of proposed rulemaking (NPRM) to reform rules of practice at the Patent Trial and Appeal Board (PTAB) as well as President Trump’s political influence at the agency. During the hearing, Squires also confirmed that the agency’s Patent Public Advisory Committee (PPAC) would soon be revived, following an offer to join PPAC extended last night to an undisclosed independent inventor.

Supreme Court Reverses $1 Billion Verdict, Rules Cox Not Contributorily Liable for Subscribers’ Copyright Infringement

The U.S. Supreme Court on Wednesday reversed a decision by the U.S. Court of Appeals for the Fourth Circuit, ruling that internet service provider Cox Communications, Inc., is not contributorily liable for its subscribers’ copyright infringement. In a 7-2 decision authored by Justice Thomas, the Court held that a service provider is contributorily liable for a user’s infringement only when it intended for its service to be used in that way, which is established only if the provider either encouraged the infringement or designed the service specifically to facilitate it.

Mercola is Seeking a Patent Paralegal

Mercola is managing a high-volume patent pipeline (~200 applications) across multiple advanced technology domains and is seeking experienced contract Patent Paralegals to support prosecution at scale. This is not a typical low-volume IP role. You will work directly with the inventor and patent counsel to ensure accuracy, consistency, and flawless USPTO filing execution across a complex and fast-moving portfolio spanning biotech, AI/software, medical devices, and consumer health innovations. This is a full-time, temporary, fully remote position (USA).

IPWatchdog LIVE Day Three: Coke Stewart Says Reexam Surge is on Office Radar; Rep. Kiley Talks Innovation Education on the Hill; and Meet the 2026 IPWatchdog Masters Hall of Fame Inductees

In the final session of IPWatchdog LIVE 2026 on Tuesday, March 24, U.S. Patent and Trademark Office (USPTO) Deputy Director Coke Morgan Stewart had a conversation with IPWatchdog Founder and CEO Gene Quinn in which she confirmed the Office is paying attention to the recent surge in ex parte reexamination filings and also said she is “optimistic” that the pending Notice of Proposed Rulemaking (NPRM) will be finalized. 

Calculating the Patent Liabilities of the ‘Magnificent Seven’

Nearly every operating company valued at greater than $20 billion in market capitalization is likely to be accused of patent infringement at some point. The high likelihood of utilizing another person or company’s patented technology led to an explosion of patent litigation activity over the last 30 years. Often, inventions emerge without a specific product in mind, and the strategy for the invention-turned-patent lacks a clear vision. This has been the way of invention since the patent offices were first formed and legal IP protection became a constitutionally ordained government program.

SCOTUS Grants Solicitor General Divided Argument in Hikma Induced Infringement Case

The U.S. Supreme Court on Monday granted the Solicitor General’s motion for leave to participate in oral argument as amicus curiae and for divided argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a case concerning induced patent infringement in the pharmaceutical skinny label context. The order followed the filing of a merits response brief by Amarin on March 20, defending the U.S. Court of Appeals for the Federal Circuit (CAFC) decision that found Amarin plausibly alleged that Hikma Pharmaceuticals actively induced infringement of patents covering uses of Amarin’s cardiovascular drug Vascepa.

IPWatchdog LIVE Panel Asks Whether Patent Licensing Still Works — The Answer Is Complicated

A panel on day one of IPWatchdog LIVE 2026 didn’t mince words: the voluntary patent licensing ecosystem is functionally broken, and the IP community needs to understand why. That was the diagnostic consensus from the panel titled Patent Dealmaking, Monetization & Licensing: An Examination of Capital, Risk, and Deal Flow, moderated by Brian O’Shaughnessy (Dinsmore & Shohl) and featuring Michael Gulliford (Soryn IP Capital), Louis Carbonneau (Tangible IP), and Dan Kesack (WTW Insurance).

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates